Prevalence of Delayed Chemotherapy Associated Nausea

Antje Koller172 enrolled

Overview

This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.

Chemotherapies are rated to have a high to minimal emetogenic potential in oncology patients. Their potential to induce delayed nausea is supposed to often be higher than their emetogenic potential. However, data on delayed chemotherapy-related nausea are scarce, which is problematic because nausea (a) has a large impact on patients quality of life and treatment decisions, (b) is often underestimated by health care professionals, (c) is less responsive to commonly used antiemetic medication, and (d) may even be different from rates that have been established in controlled clinical trials. Therefore, the aim of this study is to assess the prevalence of delayed chemotherappy-induced nausea in adult oncology patients in dayclinics.

Study Type

OBSERVATIONAL

Enrollment

172

Conditions

Chemotherapy-induced Nausea and Vomiting

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * first day of chemotherapy of a new cycle (any cycle) * speak and write German * sign the consent forms Exclusion Criteria: * cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge) * accompanying radiotherapy; * pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and * prior participation in CINrate (each person participates only once)

Locations (1)

ZeTuP

Sankt Gallen, Switzerland

Outcomes

Primary Outcomes

delayed Nausea

nausea that occurs 24 hours to 5 days after chemotherapy (100mm VAS in diary)

Time frame: Each patient: each days for 5 days after chemotherapy; recruitment: six weeks

Secondary Outcomes

acute nausea

nausea that occurs within 24 hours of chemotherapy (100mm VAS in diary)

Time frame: Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks

acute and delayed vomiting

vomiting that occurs within 5 days of chemotherapy (100mm VAS in diary)

Time frame: Each patient: each day for 5 days after chemotherapy; recruitment: six weeks

adherence to antiemetics

prescribed antiemetics compared with taken antiemetics; intake is calculated in % of the correct dose (dosing adherence) and in % of the dose at the right time (timing adherence)

Time frame: Each patient: each day for 5 days after chemotherapy; recruitment: six weeks

antiemetic prescription

antiemetic medication that is prescribed

Time frame: Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks

interference of nausea or vomiting with everyday life

Functional Living Index Cancer (FLIE)

Time frame: Each patient: measured at day 5 after chemotherapy; recruitment: six weeks

patient-related barriers to antiemetics

Nausea and Vomiting Management Barriers Questionnaire (NVMBQ)

Time frame: Each patient: measured at day 5 after chemotherapy; recruitment: six weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.